vs

Side-by-side financial comparison of CONSUMER PORTFOLIO SERVICES, INC. (CPSS) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.

CONSUMER PORTFOLIO SERVICES, INC. is the larger business by last-quarter revenue ($109.4M vs $70.6M, roughly 1.6× Viridian Therapeutics, Inc.\DE). CONSUMER PORTFOLIO SERVICES, INC. runs the higher net margin — 4.6% vs -49.0%, a 53.6% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 3.9%). CONSUMER PORTFOLIO SERVICES, INC. produced more free cash flow last quarter ($288.3M vs $-84.7M).

Consumer Portfolio Services, Inc. is a U.S. specialty finance firm providing indirect auto loan financing and servicing for consumers with limited or subprime credit. It partners with franchised and independent car dealerships nationwide to originate installment contracts for new and used vehicle purchases.

Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.

CPSS vs VRDN — Head-to-Head

Bigger by revenue
CPSS
CPSS
1.6× larger
CPSS
$109.4M
$70.6M
VRDN
Growing faster (revenue YoY)
VRDN
VRDN
+81954.2% gap
VRDN
81958.1%
3.9%
CPSS
Higher net margin
CPSS
CPSS
53.6% more per $
CPSS
4.6%
-49.0%
VRDN
More free cash flow
CPSS
CPSS
$373.0M more FCF
CPSS
$288.3M
$-84.7M
VRDN

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CPSS
CPSS
VRDN
VRDN
Revenue
$109.4M
$70.6M
Net Profit
$5.0M
$-34.6M
Gross Margin
Operating Margin
6.6%
-56.7%
Net Margin
4.6%
-49.0%
Revenue YoY
3.9%
81958.1%
Net Profit YoY
-3.2%
54.9%
EPS (diluted)
$0.21

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CPSS
CPSS
VRDN
VRDN
Q4 25
$109.4M
Q3 25
$108.4M
$70.6M
Q2 25
$109.8M
Q1 25
$106.9M
Q4 24
$105.3M
Q3 24
$100.6M
Q2 24
$95.9M
Q1 24
$91.7M
Net Profit
CPSS
CPSS
VRDN
VRDN
Q4 25
$5.0M
Q3 25
$4.9M
$-34.6M
Q2 25
$4.8M
Q1 25
$4.7M
Q4 24
$5.1M
Q3 24
$4.8M
Q2 24
$4.7M
Q1 24
$4.6M
Operating Margin
CPSS
CPSS
VRDN
VRDN
Q4 25
6.6%
Q3 25
6.5%
-56.7%
Q2 25
6.3%
Q1 25
6.4%
Q4 24
7.0%
Q3 24
6.8%
Q2 24
7.0%
Q1 24
7.1%
Net Margin
CPSS
CPSS
VRDN
VRDN
Q4 25
4.6%
Q3 25
4.5%
-49.0%
Q2 25
4.4%
Q1 25
4.4%
Q4 24
4.9%
Q3 24
4.8%
Q2 24
4.9%
Q1 24
5.0%
EPS (diluted)
CPSS
CPSS
VRDN
VRDN
Q4 25
$0.21
Q3 25
$0.20
Q2 25
$0.20
Q1 25
$0.19
Q4 24
$0.21
Q3 24
$0.20
Q2 24
$0.19
Q1 24
$0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CPSS
CPSS
VRDN
VRDN
Cash + ST InvestmentsLiquidity on hand
$6.3M
$490.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$309.5M
$503.0M
Total Assets
$3.9B
$577.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CPSS
CPSS
VRDN
VRDN
Q4 25
$6.3M
Q3 25
$9.4M
$490.9M
Q2 25
$15.8M
Q1 25
$29.8M
Q4 24
$11.7M
Q3 24
$8.1M
Q2 24
$9.8M
Q1 24
$13.2M
Stockholders' Equity
CPSS
CPSS
VRDN
VRDN
Q4 25
$309.5M
Q3 25
$307.6M
$503.0M
Q2 25
$303.1M
Q1 25
$298.4M
Q4 24
$292.8M
Q3 24
$285.1M
Q2 24
$280.3M
Q1 24
$279.1M
Total Assets
CPSS
CPSS
VRDN
VRDN
Q4 25
$3.9B
Q3 25
$3.8B
$577.1M
Q2 25
$3.8B
Q1 25
$3.7B
Q4 24
$3.5B
Q3 24
$3.5B
Q2 24
$3.3B
Q1 24
$3.0B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CPSS
CPSS
VRDN
VRDN
Operating Cash FlowLast quarter
$289.0M
$-84.6M
Free Cash FlowOCF − Capex
$288.3M
$-84.7M
FCF MarginFCF / Revenue
263.5%
-120.1%
Capex IntensityCapex / Revenue
0.6%
0.2%
Cash ConversionOCF / Net Profit
58.02×
TTM Free Cash FlowTrailing 4 quarters
$500.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CPSS
CPSS
VRDN
VRDN
Q4 25
$289.0M
Q3 25
$84.9M
$-84.6M
Q2 25
$54.5M
Q1 25
$73.9M
Q4 24
$233.8M
Q3 24
$69.8M
Q2 24
$43.3M
Q1 24
$52.7M
Free Cash Flow
CPSS
CPSS
VRDN
VRDN
Q4 25
$288.3M
Q3 25
$84.9M
$-84.7M
Q2 25
$54.3M
Q1 25
$73.4M
Q4 24
$233.3M
Q3 24
$69.7M
Q2 24
$43.1M
Q1 24
$52.6M
FCF Margin
CPSS
CPSS
VRDN
VRDN
Q4 25
263.5%
Q3 25
78.3%
-120.1%
Q2 25
49.5%
Q1 25
68.7%
Q4 24
221.6%
Q3 24
69.3%
Q2 24
45.0%
Q1 24
57.3%
Capex Intensity
CPSS
CPSS
VRDN
VRDN
Q4 25
0.6%
Q3 25
0.0%
0.2%
Q2 25
0.1%
Q1 25
0.4%
Q4 24
0.4%
Q3 24
0.1%
Q2 24
0.2%
Q1 24
0.1%
Cash Conversion
CPSS
CPSS
VRDN
VRDN
Q4 25
58.02×
Q3 25
17.50×
Q2 25
11.35×
Q1 25
15.74×
Q4 24
45.43×
Q3 24
14.55×
Q2 24
9.27×
Q1 24
11.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons